| Product |
Cell Type |
Description |
Indication |
R&D |
PreClinical |
Clinical |
Collaboration |
| iPSC-derived, Off-the-Shelf Cell Products |
| FT500 |
iPSC-NK |
iNK Cell |
+CPB in Solid Tumors |
|
|
| FT516 |
iPSC-NK |
hnCD16 iNK Cell |
+mAb in Hematologic Malignancies |
|
|
| FT596 |
iPSC-NK |
CAR19 + hnCD16 + IL15/R iNK Cell |
Hematologic Malignancies |
|
|
| FT538 |
iPSC-NK |
CD38-less + hnCD16 + IL15/R iNK Cell |
+anti-CD38 mAb in Multiple Myeloma |
|
|
| FT819 |
iPSC-T |
TCR-less, TRAC-Targeted CAR19 iT |
Hematologic Malignancies |
|
|
| FT5xx |
iPSC-NK |
Multi-faceted engineered attributes |
Solid Tumors |
|
|
| FT8xx |
iPSC-T |
Multi-faceted engineered attributes |
Hematologic Malignancies |
|
 |
| FT8xx |
iPSC-T |
Multi-faceted engineered attributes |
Solid Tumors |
|
|
| FT301 |
iPSC-MDSC |
Engineered immuno-suppresive attributes |
Not disclosed |
|
|
| Donor-derived Cell Products |
| ProTmune™ |
Hematopoietic graft |
Allogeneic mPB cell graft |
Hematologic Malignancies |
|
|
| NK100 |
NK |
Adaptive Memory NK Cells |
AML |
|
|
| NK100 |
NK |
Adaptive Memory NK Cells |
Ovarian Cancer |
|
|
| NK100 |
NK |
Adaptive Memory NK Cells |
+/- mAb in Solid Tumors |
|
|